+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Changes in anti-müllerian hormone levels as a biomarker for ovarian reserve after ultrasound-guided high-intensity focused ultrasound treatment of adenomyosis and uterine fibroid



Changes in anti-müllerian hormone levels as a biomarker for ovarian reserve after ultrasound-guided high-intensity focused ultrasound treatment of adenomyosis and uterine fibroid



Bjog 124(Suppl. 3): 18-22



To assess the changes in antimüllerian hormone (AMH) levels after ablation for symptomatic uterine fibroids and adenomyosis using ultrasound-guided high-intensity focused ultrasound (USgHIFU). A prospective study. Gynaecological department in multiple hospitals in South Korea. Patients with uterus fibroids and adenomyosis. Seventy-nine women with symptomatic uterine fibroids and adenomyosis who met the inclusion criteria were enrolled in our study between January 2014 and December 2014. All patients underwent USgHIFU ablations. Each patient was examined before and after treatment, and at 6 and 12 months after treatment by T2-weighted MRI imaging (T2WI) and T1-weighted MRI imaging (T1WI) with gadolinium injection. Symptom severity scores (SSS), Uterine Fibroid Symptom Quality of Life (UFS-QOL) questionnaire subscales, and reductions of treated volume were assessed. AMH levels before and 6 months after HIFU ablation were compared to determine whether USgHIFU ablation affected ovarian reserve. HIFU treatment did not affect the ovarian function. HIFU treatment time (mean ± standard deviation), HIFU ablation time, and treatment energy were 73.5 ± 25.6 minutes, 9994.7 ± 386.8 seconds, and 364 713.8 ± 156 350.7 Joules, respectively. AMH levels before and 6 months after HIFU ablation were 2.11 ± 2.66 and 1.84 ± 2.57 μg/l, respectively. There was no significant difference in AMH level between the two time points (P > 0.05). USgHIFU ablation for uterine fibroid and adenomyosis was effective without affecting ovarian reserve. HIFU ablation is a safe and effective treatment for patients with uterine fibroids and adenomyosis that does not affect ovarian function.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 059485333

Download citation: RISBibTeXText

PMID: 28856867


Related references

Ultrasound-guided high-intensity focused ultrasound treatment for uterine fibroid & adenomyosis: A single center experience from the Republic of Korea. Ultrasonics Sonochemistry 27: 682-687, 2015

Thermal bowel injury after ultrasound-guided high-intensity focused ultrasound treatment of uterine adenomyosis. Ultrasound in Obstetrics and Gynecology 52(2): 282-283, 2018

Ovarian Reserve After Ultrasound-Guided High-Intensity Focused Ultrasound for Uterine Fibroids: Preliminary Experience. Journal of Obstetrics and Gynaecology Canada 38(4): 357-361, 2016

Clinical Predictors of Long-term Success in Ultrasound-guided High-intensity Focused Ultrasound Ablation Treatment for Adenomyosis: A Retrospective Study. Medicine 95(3): E2443, 2016

Ultrasound-guided high-intensity focused ultrasound (USgHIFU) ablation for the treatment of patients with adenomyosis and prior abdominal surgical scars: A retrospective study. International Journal of Hyperthermia 31(7): 777-783, 2015

Automatic segmentation for detecting uterine fibroid regions treated with MR-guided high intensity focused ultrasound (MR-HIFU). Medical Physics 41(7): 073502, 2014

Noninvasive, in vivo determination of uterine fibroid thermal conductivity in MRI-guided high intensity focused ultrasound therapy. Journal of Magnetic Resonance Imaging 41(6): 1654-1661, 2015

Effective ablation therapy of adenomyosis with ultrasound-guided high-intensity focused ultrasound. International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics 124(3): 207-211, 2014

Ultrasound-guided high-intensity focused ultrasound in the treatment of uterine fibroids. Medicine 98(10): E14566, 2019

Feasibility of MRI-guided high intensity focused ultrasound treatment for adenomyosis. European Journal of Radiology 81(11): 3624-3630, 2012

Ultrasound-guided high-intensity focused ultrasound ablation for adenomyosis: the clinical experience of a single center. Fertility and Sterility 95(3): 900-905, 2011

A comparison of the cost-utility of ultrasound-guided high-intensity focused ultrasound and hysterectomy for adenomyosis: a retrospective study. Bjog 124(Suppl. 3): 40-45, 2017

Safety of ultrasound-guided high-intensity focused ultrasound ablation for diffuse adenomyosis: A retrospective cohort study. Ultrasonics Sonochemistry 36: 139-145, 2017

Vaginal delivery outcomes of pregnancies following ultrasound-guided high-intensity focused ultrasound ablation treatment for uterine fibroids. International Journal of Hyperthermia 35(1): 510-517, 2018

Ultrasound guided high-intensity focused ultrasound combined with gonadotropin releasing hormone analogue (GnRHa) ablating uterine leiomyoma with homogeneous hyperintensity on T 2 weighted MR imaging. British Journal of Radiology 90(1073): 20160760, 2017